Search

Your search keyword '"Chokshi, Dhruti"' showing total 10 results
Start Over Author "Chokshi, Dhruti" Publication Year Range Last 3 years
10 results on '"Chokshi, Dhruti"'

1. S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Lee, Hans C., primary, Bumma, Naresh, additional, Richter, Joshua, additional, Dhodapkar, Madhav, additional, Hoffman, James E., additional, Suvannasankha, Attaya, additional, Zonder, Jeffrey, additional, Shah, Mansi R., additional, Lentzsch, Suzanne, additional, Maly, Joseph J., additional, Ye, Jing Christine, additional, Wu, Ka Lung, additional, Deveaux, Michelle, additional, Chokshi, Dhruti, additional, Boyapati, Anita, additional, Hazra, Anasuya, additional, Lorenc, Karen Rodriguez, additional, Kroog, Glenn, additional, Houvras, Yariv, additional, and Jagannath, Sundar, additional

Published
2023
Full Text
View/download PDF

2. MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

Author

Zonder, Jeffrey A., Richter, Joshua, Bumma, Naresh, Brayer, Jason, Hoffman, James E., Bensinger, William I., Wu, Ka Lung, Xu, Linzhi, Chokshi, Dhruti, Boyapati, Anita, Cronier, Damien, Houvras, Yariv, Lorenc, Karen Rodriguez, Kroog, Glenn S., Dhodapkar, Madhav V., Lentzsch, Suzanne, Cooper, Dennis, and Jagannath, Sundar

Published
2022
Full Text
View/download PDF

3. Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Author

Bumma, Naresh, primary, Richter, Joshua, additional, Brayer, Jason, additional, Zonder, Jeffrey A., additional, Dhodapkar, Madhav, additional, Shah, Mansi R., additional, Hoffman, James E., additional, Mawad, Raya, additional, Maly, Joseph J., additional, Lentzsch, Suzanne, additional, Suvannasankha, Attaya, additional, Roy, Pourab, additional, Dey, Jyotirmoy, additional, Chokshi, Dhruti, additional, Boyapati, Anita, additional, Visich, Jenn, additional, Houvras, Yariv, additional, Rodriguez Lorenc, Karen, additional, Kroog, Glenn S., additional, and Jagannath, Sundar, additional

Published
2022
Full Text
View/download PDF

4. OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma

Author

Zonder, Jeffrey, primary, Richter, Joshua, additional, Bumma, Naresh, additional, Brayer, Jason, additional, Hoffman, James E., additional, Bensinger, William I., additional, Wu, Ka Lung, additional, Xu, Linzhi, additional, Chokshi, Dhruti, additional, Boyapati, Anita, additional, Cronier, Damien, additional, Houvras, Yariv, additional, Lorenc, Karen Rodriguez, additional, Kroog, Glenn S., additional, Dhodapkar, Madhav V., additional, Lentzsch, Suzanne, additional, Cooper, Dennis, additional, and Jagannath, Sundar, additional

Published
2022
Full Text
View/download PDF

5. Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Zonder, Jeffrey A., primary, Richter, Joshua, additional, Bumma, Naresh, additional, Brayer, Jason, additional, Hoffman, James E, additional, Bensinger, William I., additional, Wu, Ka Lung, additional, Xu, Linzhi, additional, Chokshi, Dhruti, additional, Boyapati, Anita, additional, Sharma, Manish, additional, Rodriguez Lorenc, Karen, additional, Kroog, Glenn S, additional, Dhodapkar, Madhav V, additional, Lentzsch, Suzanne, additional, Cooper, Dennis, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

7. Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Author

Jagannath, Sundar, Richter, Joshua, Dhodapkar, Madhav V., Hoffman, James E., Lee, Hans C., Suvannasankha, Attaya, Shah, Mansi R., Lentzsch, Suzanne, Zonder, Jeffrey A., Baz, Rachid, Maly, Joseph J., Namburi, Swathi, Wu, Ka Lung, Pianko, Matthew, Ye, Jing Christine, Silbermann, Rebecca, Min, Chang-Ki, Vekemans, Marie-Christiane, Munder, Markus, Byun, Ja Min, Lopez, Joaquín Martínez, DeVeaux, Michelle, Chokshi, Dhruti, Boyapati, Anita, Hazra, Anasuya, Rodriguez Lorenc, Karen, Kroog, Glenn S., Houvras, Yariv, and Bumma, Naresh

Abstract

Background

Published
2023
Full Text
View/download PDF

8. Poster: MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

Author

Zonder, Jeffrey A., Richter, Joshua, Bumma, Naresh, Brayer, Jason, Hoffman, James E., Bensinger, William I., Wu, Ka Lung, Xu, Linzhi, Chokshi, Dhruti, Boyapati, Anita, Cronier, Damien, Houvras, Yariv, Lorenc, Karen Rodriguez, Kroog, Glenn S., Dhodapkar, Madhav V., Lentzsch, Suzanne, Cooper, Dennis, and Jagannath, Sundar

Published
2022
Full Text
View/download PDF

9. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

Author

Lee, Hans C., Bumma, Naresh, Richter, Joshua Ryan, Dhodapkar, Madhav V., Hoffman, James E., Suvannasankha, Attaya, Zonder, Jeffrey A., Shah, Mansi R., Lentzsch, Suzanne, Maly, Joseph J., Ye, Jing Christine, Lung Wu, Ka, DeVeaux, Michelle, Chokshi, Dhruti, Boyapati, Anita, Hazra, Anasuya, Rodriguez-Lorenc, Karen, Kroog, Glenn Scott, Houvras, Yariv J., and Jagannath, Sundar

Published
2023
Full Text
View/download PDF

10. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.

Author

Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martínez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, and Dhodapkar MV

Subjects
Humans, Aged, Male, Female, Middle Aged, Aged, 80 and over, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen immunology, Adult, Neoplasm Recurrence, Local drug therapy, Multiple Myeloma drug therapy, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific adverse effects, Antibodies, Bispecific administration & dosage
Abstract

Purpose: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM)., Methods: Phase II eligible patients had RRMM that either progressed on/after ≥three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI/IMiD/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks. Phase II 200 mg patients who achieved a ≥very good partial response by week 24 received linvoseltamab once every 4 weeks. The primary end point in phase II was overall response rate (ORR)., Results: Among the 117 patients treated with 200 mg, the median age was 70 years, 39% had high-risk cytogenetics, and 28% had penta-refractory disease. At a median follow-up of 14.3 months, the ORR was 71%, with 50% achieving ≥complete response (CR). In 104 patients treated with 50 mg at a median follow-up of 7.4 months, the ORR was 48%, with 21% achieving ≥CR. The median duration of response (DOR) for 200 mg patients (n = 83) was 29.4 months (95% CI, 19.2 to not evaluable). Among 200 mg patients, the most common adverse events included cytokine release syndrome (35.0% Gr1, 10.3% Gr2, 0.9% Gr3), neutropenia (0.9% Gr2, 18.8% Gr3, 23.1% Gr4), and anemia (3.4% Gr1, 4.3% Gr2, 30.8% Gr3). Immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients (2.6% each Gr1, Gr2, Gr3). Infections were reported in 74.4% of patients (33.3% Gr3, 2.6% Gr4); infection frequency and severity declined over time., Conclusion: Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results